Showing results (1461-1470 of 1,560) with videos related to

Sort By:
Pageof 156
Annals of Nuclear Medicine|July 2, 2011
Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide surveyTakeshi Murano, Ryogo Minamimoto, Michio Senda, et al.
Current Biology : CB|September 5, 2020
Developmental Modulation of Root Cell Wall Architecture Confers Resistance to an Oomycete PathogenAleksandr Gavrin, Thomas Rey, Thomas A Torode, et al.
Communications Biology|March 11, 2022
Overall structure of fully assembled cyanobacterial KaiABC circadian clock complex by an integrated experimental-computational approachYasuhiro Yunoki, Atsushi Matsumoto, Ken Morishima, et al.
Cell Reports. Medicine|July 27, 2025
Imeglimin suppresses glucagon secretion and induces a loss of α cell identityTakahiro Tsuno, Jinghe Li, Kuniyuki Nishiyama, et al.
Mbio|March 1, 2018
Gene Flow between Divergent Cereal- and Grass-Specific Lineages of the Rice Blast Fungus Magnaporthe oryzaePierre Gladieux, Bradford Condon, Sebastien Ravel, et al.
JACC. Asia|April 1, 2026
Transcatheter Aortic Valve Replacement in Functionally Dependent Patients: Analysis Using a Government-Adjudicated Long-Term Care CertificationYuki Harashima, Taishi Okuno, Toshiya Yoshida, et al.
Plant Physiology|June 3, 2024
Two structurally different oomycete lipophilic microbe-associated molecular patterns induce distinctive plant immune responsesMohammad Shahjahan Monjil, Hiroaki Kato, Satomi Ota, et al.
The Journal of Biological Chemistry|November 15, 2008
Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathwaysTaku Watanabe, Naoto Kubota, Mitsuru Ohsugi, et al.
British Journal of Haematology|March 13, 2014
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaMichinori Ogura, Kiyoshi Ando, Tatsuya Suzuki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphomaKen Ohmachi, Nozomi Niitsu, Toshiki Uchida, et al.
Pageof 156